John F. Crowley net worth and biography

John Crowley Biography and Net Worth

Executive Chairman of Amicus Therapeutics
John F. Crowley is our Executive Chairman and former CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, “The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children.” The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.

John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame and the Wall Street Journal CEO Council. Currently, John serves as a member of the Intellia Therapeutics, Inc. Board of Directors. He is the former National Chairman of the Make-A-Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.

What is John F. Crowley's net worth?

The estimated net worth of John F. Crowley is at least $9.17 million as of September 15th, 2022. Mr. Crowley owns 856,897 shares of Amicus Therapeutics stock worth more than $9,168,798 as of October 3rd. This net worth evaluation does not reflect any other investments that Mr. Crowley may own. Additionally, Mr. Crowley receives a salary of $2,060,000.00 as Executive Chairman at Amicus Therapeutics. Learn More about John F. Crowley's net worth.

How old is John F. Crowley?

Mr. Crowley is currently 55 years old. There are 5 older executives and no younger executives at Amicus Therapeutics. Learn More on John F. Crowley's age.

What is John F. Crowley's salary?

As the Executive Chairman of Amicus Therapeutics, Inc., Mr. Crowley earned a total compensation package of $1,626,112.00 in 2021. Mr. Crowley earned a salary of $440,713.00, options awards of $979,441.00, non-equity compensation of $159,691.00, and other compensation of $46,266.00. Learn More on John F. Crowley's salary.

How do I contact John F. Crowley?

The corporate mailing address for Mr. Crowley and other Amicus Therapeutics executives is 1 Cedar Brook Drive, Cranbury NJ, 08512. Amicus Therapeutics can also be reached via phone at (215) 921-7600 and via email at [email protected] Learn More on John F. Crowley's contact information.

Has John F. Crowley been buying or selling shares of Amicus Therapeutics?

John F. Crowley has not been actively trading shares of Amicus Therapeutics over the course of the past ninety days. Learn More on John F. Crowley's trading history.

Who are Amicus Therapeutics' active insiders?

Amicus Therapeutics' insider roster includes Lynn Bleil (Director), Bradley Campbell (CEO), Bradley Campbell (CEO), John Crowley (Executive Chairman), Margaret Mcglynn (Director), Samantha Prout (Insider), and Burke Whitman (Director). Learn More on Amicus Therapeutics' active insiders.

Are insiders buying or selling shares of Amicus Therapeutics?

During the last year, Amicus Therapeutics insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $15,735.00. During the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 364,519 shares worth more than $3,834,800.59. The most recent insider tranaction occured on September, 15th when Chairman John F Crowley sold 10,468 shares worth more than $111,588.88. Insiders at Amicus Therapeutics own 2.4 % of the company. Learn More about insider trades at Amicus Therapeutics.

Information on this page was last updated on 9/15/2022.

John F. Crowley Insider Trading History at Amicus Therapeutics

See Full Table

John F. Crowley Buying and Selling Activity at Amicus Therapeutics

This chart shows John F. Crowley's buying and selling at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amicus Therapeutics Company Overview

Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $10.70
Low: $10.44
High: $11.00

50 Day Range

MA: $11.20
Low: $9.82
High: $12.75

2 Week Range

Now: $10.70
Low: $5.91
High: $12.96

Volume

2,593,637 shs

Average Volume

3,315,908 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89